299 related articles for article (PubMed ID: 18060046)
1. Tumor escape in a Wnt1-dependent mouse breast cancer model is enabled by p19Arf/p53 pathway lesions but not p16 Ink4a loss.
Debies MT; Gestl SA; Mathers JL; Mikse OR; Leonard TL; Moody SE; Chodosh LA; Cardiff RD; Gunther EJ
J Clin Invest; 2008 Jan; 118(1):51-63. PubMed ID: 18060046
[TBL] [Abstract][Full Text] [Related]
2. Ink4a/Arf tumor suppressor does not modulate the degenerative conditions or tumor spectrum of the telomerase-deficient mouse.
Khoo CM; Carrasco DR; Bosenberg MW; Paik JH; Depinho RA
Proc Natl Acad Sci U S A; 2007 Mar; 104(10):3931-6. PubMed ID: 17360455
[TBL] [Abstract][Full Text] [Related]
3. The differential impact of p16(INK4a) or p19(ARF) deficiency on cell growth and tumorigenesis.
Sharpless NE; Ramsey MR; Balasubramanian P; Castrillon DH; DePinho RA
Oncogene; 2004 Jan; 23(2):379-85. PubMed ID: 14724566
[TBL] [Abstract][Full Text] [Related]
4. Both p16(Ink4a) and the p19(Arf)-p53 pathway constrain progression of pancreatic adenocarcinoma in the mouse.
Bardeesy N; Aguirre AJ; Chu GC; Cheng KH; Lopez LV; Hezel AF; Feng B; Brennan C; Weissleder R; Mahmood U; Hanahan D; Redston MS; Chin L; Depinho RA
Proc Natl Acad Sci U S A; 2006 Apr; 103(15):5947-52. PubMed ID: 16585505
[TBL] [Abstract][Full Text] [Related]
5. Resistance of primary cultured mouse hepatic tumor cells to cellular senescence despite expression of p16(Ink4a), p19(Arf), p53, and p21(Waf1/Cip1).
Obata M; Imamura E; Yoshida Y; Goto J; Kishibe K; Yasuda A; Ogawa K
Mol Carcinog; 2001 Sep; 32(1):9-18. PubMed ID: 11568971
[TBL] [Abstract][Full Text] [Related]
6. Impact of p53 loss on reversal and recurrence of conditional Wnt-induced tumorigenesis.
Gunther EJ; Moody SE; Belka GK; Hahn KT; Innocent N; Dugan KD; Cardiff RD; Chodosh LA
Genes Dev; 2003 Feb; 17(4):488-501. PubMed ID: 12600942
[TBL] [Abstract][Full Text] [Related]
7. The role of Ink4a/Arf in ErbB2 mammary gland tumorigenesis.
D'Amico M; Wu K; Di Vizio D; Reutens AT; Stahl M; Fu M; Albanese C; Russell RG; Muller WJ; White M; Negassa A; Lee HW; DePinho RA; Pestell RG
Cancer Res; 2003 Jun; 63(12):3395-402. PubMed ID: 12810676
[TBL] [Abstract][Full Text] [Related]
8. The inhibitor of cyclin-dependent kinase 4a/alternative reading frame (INK4a/ARF) locus encoded proteins p16INK4a and p19ARF repress cyclin D1 transcription through distinct cis elements.
D'Amico M; Wu K; Fu M; Rao M; Albanese C; Russell RG; Lian H; Bregman D; White MA; Pestell RG
Cancer Res; 2004 Jun; 64(12):4122-30. PubMed ID: 15205322
[TBL] [Abstract][Full Text] [Related]
9. Obligate roles for p16(Ink4a) and p19(Arf)-p53 in the suppression of murine pancreatic neoplasia.
Bardeesy N; Morgan J; Sinha M; Signoretti S; Srivastava S; Loda M; Merlino G; DePinho RA
Mol Cell Biol; 2002 Jan; 22(2):635-43. PubMed ID: 11756558
[TBL] [Abstract][Full Text] [Related]
10. Dual inactivation of RB and p53 pathways in RAS-induced melanomas.
Bardeesy N; Bastian BC; Hezel A; Pinkel D; DePinho RA; Chin L
Mol Cell Biol; 2001 Mar; 21(6):2144-53. PubMed ID: 11238948
[TBL] [Abstract][Full Text] [Related]
11. p19Arf suppresses growth, progression, and metastasis of Hras-driven carcinomas through p53-dependent and -independent pathways.
Kelly-Spratt KS; Gurley KE; Yasui Y; Kemp CJ
PLoS Biol; 2004 Aug; 2(8):E242. PubMed ID: 15314658
[TBL] [Abstract][Full Text] [Related]
12. Inactivation of the Wip1 phosphatase inhibits mammary tumorigenesis through p38 MAPK-mediated activation of the p16(Ink4a)-p19(Arf) pathway.
Bulavin DV; Phillips C; Nannenga B; Timofeev O; Donehower LA; Anderson CW; Appella E; Fornace AJ
Nat Genet; 2004 Apr; 36(4):343-50. PubMed ID: 14991053
[TBL] [Abstract][Full Text] [Related]
13. Mutational analysis of selected genes in the TGFbeta, Wnt, pRb, and p53 pathways in primary uveal melanoma.
Edmunds SC; Kelsell DP; Hungerford JL; Cree IA
Invest Ophthalmol Vis Sci; 2002 Sep; 43(9):2845-51. PubMed ID: 12202501
[TBL] [Abstract][Full Text] [Related]
14. A p53/ARF-dependent anticancer barrier activates senescence and blocks tumorigenesis without impacting apoptosis.
Sinha VC; Qin L; Li Y
Mol Cancer Res; 2015 Feb; 13(2):231-8. PubMed ID: 25253740
[TBL] [Abstract][Full Text] [Related]
15. Mice with alterations in both p53 and Ink4a/Arf display a striking increase in lung tumor multiplicity and progression: differential chemopreventive effect of budesonide in wild-type and mutant A/J mice.
Wang Y; Zhang Z; Kastens E; Lubet RA; You M
Cancer Res; 2003 Aug; 63(15):4389-95. PubMed ID: 12907609
[TBL] [Abstract][Full Text] [Related]
16. Oncogenic ras activates the ARF-p53 pathway to suppress epithelial cell transformation.
Lin AW; Lowe SW
Proc Natl Acad Sci U S A; 2001 Apr; 98(9):5025-30. PubMed ID: 11309506
[TBL] [Abstract][Full Text] [Related]
17. Depletion of ERK2 but not ERK1 abrogates oncogenic Ras-induced senescence.
Shin J; Yang J; Lee JC; Baek KH
Cell Signal; 2013 Dec; 25(12):2540-7. PubMed ID: 23993963
[TBL] [Abstract][Full Text] [Related]
18. p53 and p16
Azzopardi S; Pang S; Klimstra DS; Du YN
Neoplasia; 2016 Oct; 18(10):610-617. PubMed ID: 27664376
[TBL] [Abstract][Full Text] [Related]
19. Definition of three minimal deleted regions by comprehensive allelotyping and mutational screening of FHIT,p16(INK4A), and p19(ARF) genes in nasopharyngeal carcinoma.
Ko JY; Lee TC; Hsiao CF; Lin GL; Yen SH; Chen KY; Hsiung CA; Chen PJ; Hsu MM; Jou YS
Cancer; 2002 Apr; 94(7):1987-96. PubMed ID: 11932901
[TBL] [Abstract][Full Text] [Related]
20. Genomic instability, mutations and expression analysis of the tumour suppressor genes p14(ARF), p15(INK4b), p16(INK4a) and p53 in actinic keratosis.
Kanellou P; Zaravinos A; Zioga M; Stratigos A; Baritaki S; Soufla G; Zoras O; Spandidos DA
Cancer Lett; 2008 Jun; 264(1):145-61. PubMed ID: 18331779
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
